trial

Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole

NCTId NCT00205660
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 51 (actual)
Sponsored by Washington University School of Medicine
Primary completion 2009-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
51 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2005-02
Primary completion
2009-08
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
StayersSwitchers

Sponsors

Washington University School of MedicineLead Sponsor
Bristol-MyersCollaborator

Investigators

1
John W. Newcomer, MDPrincipal Investigator

Sites

1 total
St Louis, United States

Facts & assertions

4 sourced
Enrollment
51
Phase
PHASE4
Primary Completion Date
2009-08
Status
COMPLETED
relationships
The graph out of here
drug
Stayers
drug
Switchers
drug
lead_sponsor
Washington University School of Medicine
company
collaborator
Bristol-Myers
company
indication
Dyslipidemias
indication
Type 2 Diabetes Mellitus
indication
Hyperglycemia
indication
investigator
John W. Newcomer, MD
person